Clinical, laboratory, and therapeutic features of 48 cases of BPDCN with leukemic spread (BPDCL) diagnosed in 39 Italian centers referring to the GIMEMA group for the period 2018 to 2019
| . | N (%) . |
|---|---|
| New diagnosis of AML | 2686 |
| BPDCN With leukemic spread (BPDCL) Without leukemic spread | 68 48 (71) 20 (29) |
| BPDCL | 48/2686 (1.8) |
| FLT- ITD* | 3 (6.3) |
| NPM1-ITD* | 2 (4.2) |
| Males/females (ratio) | 36/12 (3/1) |
| Age (y) <60 >60 | 16 (33.3) 32 (66.7) |
| Time at diagnosis (wk) <4 >4 | 24 (50) 24 (50) |
| CNS involvement At onset At relapse | 6 (12.5) 4 2 |
| Therapeutical approaches Conventional chemotherapy BSC | 44† 39 (88.6) 5 (11.4) |
| CR after chemotherapy | 21/39 (54) |
| alloHSCT | 20/44 (45) |
| OS (mo) <6 6-12 >12 | 10 (20.8) 19 (39.6) 19 (39.6) |
| . | N (%) . |
|---|---|
| New diagnosis of AML | 2686 |
| BPDCN With leukemic spread (BPDCL) Without leukemic spread | 68 48 (71) 20 (29) |
| BPDCL | 48/2686 (1.8) |
| FLT- ITD* | 3 (6.3) |
| NPM1-ITD* | 2 (4.2) |
| Males/females (ratio) | 36/12 (3/1) |
| Age (y) <60 >60 | 16 (33.3) 32 (66.7) |
| Time at diagnosis (wk) <4 >4 | 24 (50) 24 (50) |
| CNS involvement At onset At relapse | 6 (12.5) 4 2 |
| Therapeutical approaches Conventional chemotherapy BSC | 44† 39 (88.6) 5 (11.4) |
| CR after chemotherapy | 21/39 (54) |
| alloHSCT | 20/44 (45) |
| OS (mo) <6 6-12 >12 | 10 (20.8) 19 (39.6) 19 (39.6) |